Novo Nordisk A/S

Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

By Rebecca Robbins

Company Reports Drugs (Pharmaceuticals) GLP-1 RAs (Drug) International Trade and World Market Jorgensen, Lars Fruergaard Novo Nordisk A/S

Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

By Eshe Nelson

Drugs (Pharmaceuticals) GLP-1 RAs (Drug) Health and Human Services Department Health Insurance and Managed Care Medicare Novo Nordisk A/S Obesity Ozempic (Drug) Prices (Fares, Fees and Rates) United States Politics and Government Weight

Medicare to Negotiate Lower Prices for Weight-Loss Drugs

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

By Rebecca Robbins

AstraZeneca PLC Biden, Joseph R Jr Boehringer Ingelheim GmbH Bristol Myers Squibb Company Drugs (Pharmaceuticals) Eli Lilly and Company Harris, Kamala D Inflation Reduction Act of 2022 Johnson & Johnson Medicare Merck & Company Inc Novartis AG Novo Nordisk A/S Pfizer Inc Presidential Election of 2024 Trump, Donald J United States Politics and Government

U.S. Unveils Price Limits for 10 Costly or Common Medications

The Biden administration said it would have saved $6 billion had the new prices been in effect last year.

By Noah Weiland and Rebecca Robbins